Combining human and machine intelligence to discover the next generation of therapeutic antibodies.

Therapeutic Challenge

Molecule performance is governed by a complex interplay of factors

Complex antibodies, like multispecifics, are hard to engineer because the relationship between design and function is often non-intuitive. As a consequence, conventional methods are liable to deliver sub-optimal molecules which either fail in the clinic or result in poor patient outcomes.

Our Solution

Introducing the EVA™ platform

We’ve developed EVA™ — a highly automated discovery engine that enables the rapid identification and co-optimisation of complex therapeutic antibodies across multiple key properties. 

Therapeutic Impact

Complete on/off killing selectivity for therapeutic antibodies

Our platform is both modality and format-agnostic but for our internal pipeline, we’re focussed on the development of selectivity-enhanced antibodies for the treatment of solid tumours. Our novel approach is delivering a pipeline of antibody therapeutics with best-in-class killing profiles.

Play Icon

Our Investors

Latest News

April 1, 2025

Interview | Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

February 13, 2025

Press release | LabGenius Therapeutics Appoints Three Experts to its Team of Scientific Advisors

February 5, 2025

Podcast | ‘Show me the molecule’ – On synthetic biology and cutting through AI hype